Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ReWalk Robotics Presents on Personal Exoskeleton Pricing at Medicare Public Meeting By: ReWalk Robotics Ltd. via GlobeNewswire November 30, 2023 at 16:45 PM EST MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, presented at the Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023 and provided feedback to the Centers for Medicare & Medicaid Services (“CMS”) regarding the preliminary payment determination for the code describing the ReWalk Personal Exoskeleton. “Yesterday’s meeting was an opportunity for us to show our appreciation for the significant progress that CMS has made in providing a pathway for paralyzed individuals to access life-changing exoskeleton technologies,” said Larry Jasinski, CEO of ReWalk. “It was also an opportunity to provide updated pricing information for the current ReWalk Personal Exoskeleton so that CMS can utilize these data in its payment calculations in place of the 2020 data that were used in the preliminary payment determination.” The meeting was attended by multiple representatives from CMS who had the opportunity to ask questions and seek further clarification on the materials presented. Following this public meeting, CMS is expected to review the additional information submitted by ReWalk and any other commenters, issue a final payment determination in February 2024, and implement payment rate updates to its fee schedule effective April 1, 2024. About ReWalk Robotics Ltd.ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com. For more information on the AlterG systems, please visit alterg.com. ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions. Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in ReWalk’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in ReWalk's annual report on Form 10-K and 10-K/A for the year ended December 31, 2022 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. ReWalk Media Relations:LifeSci CommunicationsE: media@rewalk.com ReWalk Investor Contact:Mike LawlessChief Financial OfficerReWalk Robotics LtdE: investorrelations@rewalk.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
ReWalk Robotics Presents on Personal Exoskeleton Pricing at Medicare Public Meeting By: ReWalk Robotics Ltd. via GlobeNewswire November 30, 2023 at 16:45 PM EST MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, presented at the Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023 and provided feedback to the Centers for Medicare & Medicaid Services (“CMS”) regarding the preliminary payment determination for the code describing the ReWalk Personal Exoskeleton. “Yesterday’s meeting was an opportunity for us to show our appreciation for the significant progress that CMS has made in providing a pathway for paralyzed individuals to access life-changing exoskeleton technologies,” said Larry Jasinski, CEO of ReWalk. “It was also an opportunity to provide updated pricing information for the current ReWalk Personal Exoskeleton so that CMS can utilize these data in its payment calculations in place of the 2020 data that were used in the preliminary payment determination.” The meeting was attended by multiple representatives from CMS who had the opportunity to ask questions and seek further clarification on the materials presented. Following this public meeting, CMS is expected to review the additional information submitted by ReWalk and any other commenters, issue a final payment determination in February 2024, and implement payment rate updates to its fee schedule effective April 1, 2024. About ReWalk Robotics Ltd.ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com. For more information on the AlterG systems, please visit alterg.com. ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions. Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in ReWalk’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in ReWalk's annual report on Form 10-K and 10-K/A for the year ended December 31, 2022 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. ReWalk Media Relations:LifeSci CommunicationsE: media@rewalk.com ReWalk Investor Contact:Mike LawlessChief Financial OfficerReWalk Robotics LtdE: investorrelations@rewalk.com
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, presented at the Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023 and provided feedback to the Centers for Medicare & Medicaid Services (“CMS”) regarding the preliminary payment determination for the code describing the ReWalk Personal Exoskeleton. “Yesterday’s meeting was an opportunity for us to show our appreciation for the significant progress that CMS has made in providing a pathway for paralyzed individuals to access life-changing exoskeleton technologies,” said Larry Jasinski, CEO of ReWalk. “It was also an opportunity to provide updated pricing information for the current ReWalk Personal Exoskeleton so that CMS can utilize these data in its payment calculations in place of the 2020 data that were used in the preliminary payment determination.” The meeting was attended by multiple representatives from CMS who had the opportunity to ask questions and seek further clarification on the materials presented. Following this public meeting, CMS is expected to review the additional information submitted by ReWalk and any other commenters, issue a final payment determination in February 2024, and implement payment rate updates to its fee schedule effective April 1, 2024. About ReWalk Robotics Ltd.ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com. For more information on the AlterG systems, please visit alterg.com. ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions. Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in ReWalk’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in ReWalk's annual report on Form 10-K and 10-K/A for the year ended December 31, 2022 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. ReWalk Media Relations:LifeSci CommunicationsE: media@rewalk.com ReWalk Investor Contact:Mike LawlessChief Financial OfficerReWalk Robotics LtdE: investorrelations@rewalk.com